{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:59:12Z","timestamp":1780412352588,"version":"3.54.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors have been shown to be effective and safe in patients with stable angina and previous myocardial infarction. However, evidence for initiating their use in patients hospitalized with acute coronary syndrome (ACS) is limited. This systematic review and meta-analysis was performed to provide more clinical evidence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>PubMed, Embase, OVID, Cochrane Library and ClinicalTrials.gov were systematically searched for eligible randomized controlled trials up to March 20, 2023. The risk ratios, standardized mean differences and 95% confidence intervals were calculated for primary and secondary outcomes. The bias risk of the included studies was assessed using the Cochrane RoB 2 criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>About 8 randomized controlled trials involving 1255 inpatients with ACS were included. PCSK9 inhibitor treatment significantly reduced low-density lipoprotein cholesterol (LDL-C) (SMD \u22121.28, 95% CI \u22121.76 to \u22120.8, <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>.001), triglycerides (TG) (SMD \u22120.93, 95% CI \u22121.82 to \u22120.05, <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>.03), total cholesterol (SMD \u22121.36, 95% CI \u22122.01 to \u22120.71, <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>.001), and apolipoprotein B (Apo B) (SMD \u22120.81, 95% CI \u22121.09 to \u22120.52, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001) within approximately 1 month. PCSK9 inhibitor treatment significantly reduced the total atheroma volume (TAV) (SMD \u22120.33, 95% CI \u22120.59 to \u22120.07, <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>.012). It also significantly increased minimum fibrous cap thickness (FCT) (SMD 0.41, 95% CI 0.22\u20130.59, <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>.001) in long-term follow-up (&gt;6 months). PCSK9 inhibitor treatment significantly reduced the risk of readmission for unstable angina (RR 0.32, 95% CI 0.12\u20130.91, <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>.032) in short-term follow-up (&lt;6 months). There were no significant differences in all-cause mortality, cardiovascular death, myocardial infarction, ischemic stroke, coronary revascularization or heart failure. Only nasopharyngitis (RR 1.71, 95% CI 1.01\u20132.91, <jats:italic toggle=\"yes\">P\u2005=\u2005<\/jats:italic>.047) adverse events were significantly observed in the PCSK9 inhibitor group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Application of a PCSK9 inhibitor in hospitalized patients with ACS reduced lipid profiles and plaque burdens and was well tolerated with few adverse events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037416","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T20:01:41Z","timestamp":1709928101000},"page":"e37416","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3060-7191","authenticated-orcid":false,"given":"Wenhai","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Sixth People\u2019s Hospital of Chengdu, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Sixth People\u2019s Hospital of Chengdu, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Sixth People\u2019s Hospital of Chengdu, Chengdu 610000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuwan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiac Ultrasound, Peking Union Medical College Hospital, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"e018897","DOI":"10.1161\/JAHA.120.018897","article-title":"Lipid management in patients presenting with acute coronary syndromes: a review.","volume":"9","author":"Claessen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"Suppl_1","key":"R7-20250503","doi-asserted-by":"crossref","first-page":"A11354","DOI":"10.1161\/circ.146.suppl_1.11354","article-title":"Abstract 11354: role of PCSK9 inhibitors in acute coronary syndromes\u2014a pilot study.","volume":"146","author":"Abdelnabi","year":"2022","journal-title":"Circulation"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome.","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS).","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction.","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial.","volume":"327","author":"Raber","year":"2022","journal-title":"JAMA"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","article-title":"Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.","volume":"18","author":"Mehta","year":"2022","journal-title":"EuroIntervention"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/FJC.0000000000000706","article-title":"Alirocumab in acute myocardial infarction: results from the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT).","volume":"74","author":"Trankle","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome\u2014the ODYSSEY J-IVUS trial.","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S0140-6736(02)07816-9","article-title":"Blinding in randomised trials: hiding who got what.","volume":"359","author":"Schulz","year":"2002","journal-title":"Lancet (London, England)"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5603\/CJ.a2016.0068","article-title":"Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients.","volume":"23","author":"Burchardt","year":"2016","journal-title":"Cardiol J"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors.","volume":"72","author":"Rosenson","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study.","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","article-title":"Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins\u2014ODYSSEY JAPAN randomized controlled trial.","volume":"80","author":"Teramoto","year":"2016","journal-title":"Circ J"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-022-01542-4","article-title":"PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis.","volume":"21","author":"Wang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"e069066","DOI":"10.1136\/bmj-2021-069066","article-title":"PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.","volume":"377","author":"Hao","year":"2022","journal-title":"BMJ"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER.","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12944-022-01724-9","article-title":"In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.","volume":"21","author":"Lou","year":"2022","journal-title":"Lipids Health Dis"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"4797529","DOI":"10.1155\/2022\/4797529","article-title":"Effects of PCSK9 inhibition on coronary atherosclerosis regression of nontarget lesions after primary percutaneous coronary intervention in acute coronary syndrome patients.","volume":"2022","author":"Li","year":"2022","journal-title":"J Interv Cardiol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2012.10.054","article-title":"Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques.","volume":"61","author":"Narula","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.jacc.2014.01.061","article-title":"Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study.","volume":"63","author":"Tian","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/eurheartj\/ehz520","article-title":"Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study.","volume":"41","author":"Prati","year":"2020","journal-title":"Eur Heart J"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"7362551","DOI":"10.1155\/2023\/7362551","article-title":"An Updated meta-analysis for safety evaluation of alirocumab and evolocumab as PCSK9 inhibitors.","volume":"2023","author":"Choi","year":"2023","journal-title":"Cardiovasc Ther"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"e31199","DOI":"10.1097\/MD.0000000000031199","article-title":"Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: a PRISMA-compliant meta-analysis.","volume":"101","author":"Liang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jacc.2013.09.048","article-title":"AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).","volume":"63","author":"Desai","year":"2014","journal-title":"J Am Coll Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:22:31Z","timestamp":1746318151000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037416","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}